Caisse DE Depot ET Placement DU Quebec Increases Stake in Boston Scientific Corporation $BSX

Key Points

• Caisse DE Depot ET Placement DU Quebec increased its stake in Boston Scientific Corporation by 12.2% during the first quarter, now owning approximately 2,056,096 shares valued at about $207.4 million.
• Boston Scientific recently reported $5.06 billion in revenue for the last quarter, exceeding analysts' expectations, with a year-over-year revenue increase of 22.8%.
• Various hedge funds have modified their positions in Boston Scientific, with 89.07% of the stock owned by institutional investors, reflecting strong confidence in the company.

Caisse DE Depot ET Placement DU Quebec lifted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 12.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,056,096 shares of the medical equipment provider's stock after purchasing an additional 223,502 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned about 0.14% of Boston Scientific worth $207,419,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific in the 1st quarter valued at approximately $27,000. Investment Management Corp VA ADV purchased a new position in shares of Boston Scientific in the 4th quarter valued at approximately $25,000. Colonial Trust Co SC raised its position in shares of Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the last quarter. Sunbeam Capital Management LLC purchased a new position in Boston Scientific during the 4th quarter worth approximately $26,000. Finally, Ameriflex Group Inc. purchased a new position in Boston Scientific during the 4th quarter worth approximately $31,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 345,029 shares of company stock worth $35,976,603 in the last ninety days. Company insiders own 0.50% of the company's stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $105.9950 on Monday. The company's fifty day moving average price is $104.10 and its 200 day moving average price is $102.12. Boston Scientific Corporation has a 1 year low of $78.53 and a 1 year high of $108.94. The stock has a market capitalization of $157.06 billion, a P/E ratio of 63.09, a P/E/G ratio of 2.56 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter last year, the company earned $0.62 EPS. The firm's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BSX. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Wells Fargo & Company raised their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Morgan Stanley raised their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. Truist Financial raised their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.